Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Miller BC1,2,3,4,5, Sen DR1,3,6, Al Abosy R1,3, Bi K1,3, Virkud YV7, LaFleur MW1,3,4,5,6, Yates KB1,3, Lako A8, Felt K8, Naik GS8, Manos M2,8, Gjini E2,8, Kuchroo JR4,5,6, Ishizuka JJ1,2,3, Collier JL1,3,4,5,6, Griffin GK1,3,9, Maleri S4,5, Comstock DE1,3,6, Weiss SA1,3,6, Brown FD1,3,4,5,6, Panda A1,3, Zimmer MD3, Manguso RT3, Hodi FS2,8, Rodig SJ8,9, Sharpe AH3,4,5,6, Haining WN10,11,12 1 Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 2 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 3 Broad Institute of MIT and Harvard, Cambridge, MA, USA. 4 Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA. 5 Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. 6 Division of Medical Sciences, Harvard Medical School, Boston, MA, USA. 7 Division of Pediatric Allergy and Immunology, Massachusetts General Hospital, Boston, MA, USA. 8 Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 9 Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. 10 Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. wnhaining@gmail.com. 11 Broad Institute of MIT and Harvard, Cambridge, MA, USA. wnhaining@gmail.com. 12 Division of Medical Sciences, Harvard Medical School, Boston, MA, USA. wnhaining@gmail.com